Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Equip Capital and Remagruppen in connection with the acquisition of Beredningsbart Syd
Mandate

Vinge advises Equip Capital and Remagruppen in connection with the acquisition of Beredningsbart Syd

October 23, 2023 Employment and Benefits M&A Real Estate and Construction

Vinge has advised the Norwegian private equity firm Equip Capital and its portfolio company Remagruppen in connection with the acquisition of Beredningsbart Syd AB (”BNB Syd”).

BNB Syd provides qualitative services within decontamination, demolition, recessing and waste management and conducts operations in southern Sweden. Remagruppen acquires and develops well-managed, stable and entrepreneur managed companies within the field of sustainable property maintenance.

Vinge’s team primarily consisted of Karl Klackenberg, Carl Fredrik Wachtmeister and Maximillian Bengtsson (M&A), Clara Klingspor (Construction), Olivia Onwuta (Employment) and Emma Emsjö (Project Assistant).

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025